Constrained crystaline growth factors for therapy of synovial joint surface defects

约束晶体生长因子治疗滑膜关节表面缺陷

• 批准号: 102848
• 金额: $ 27.22万
• 依托单位: CELL GUIDANCE SYSTEMS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102848
• 关键词: Constrained; crystaline; growth; factors; therapy

Osteoarthritis (OA) is a huge problem to the affected individual and the healthcare system. In the UK, 29% of adults over 45 have OA, of which 9% is severe (Arthritis Research UK) – equating to 6.5m people. It can cause severe pain in joints, for example the hip and the knee where and can cause great difficulty walking. No current treatment exists for OA with most patients needing a joint replacement. Early in the process, defects can occur in the surface of the joint, the cartilage which contribute to the developmemnt of OA. This study aims to develop a new way of repairing and regenerating cartilage defects. We will use proteins, called growth factors, that are known to help cartilage healing, and will surround them in a new covering inspired by nature, called a polyhedron protein packages (PODS). PODS allows the molecule to be released slowly which we hope will make them better able to heal the cartilage. The anticipated outcome of this project will be to provide vital data on the how effective the new treatment is. This will allow investment to be sought to make these treatments in large amounts and move to the first trials in people with OA.

骨关节炎（OA）是一个巨大的问题，受影响的个人和医疗保健系统。在英国，45岁以上的成年人中有29%患有OA，其中9%是严重的（英国关节炎研究）-相当于650万人。它会导致关节剧烈疼痛，例如髋关节和膝关节，并可能导致行走困难。目前没有治疗OA的方法，大多数患者需要关节置换。在此过程的早期，关节表面可能会出现缺陷，软骨会导致OA的发展。本研究旨在开发一种新的修复和再生软骨缺损的方法。我们将使用蛋白质，称为生长因子，已知有助于软骨愈合，并将它们包围在一个新的覆盖灵感来自自然，称为多面体蛋白质包（PODS）。PODS允许分子缓慢释放，我们希望这将使他们能够更好地治愈软骨。该项目的预期成果将提供有关新治疗方法有效性的重要数据。这将允许寻求投资，以大量进行这些治疗，并在OA患者中进行首次试验。